RxDoctor Payments Data

Jack Galbraith, MD

Family Medicine · Saint Louis, MONPI 1649373440

Payments from drug & device makers

$2,906in general payments, 2019–2025

Across 134 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$161
  • Lilly USA, LLC$108
  • Pfizer$54
  • Abbott$39
  • AstraZeneca$33
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$2,895100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)108$2,481
Novo Nordisk11$161
Lilly USA, LLC6$108
Pfizer3$54
Abbott2$39
AstraZeneca2$33
GSK1$18
Teva Pharmaceuticals USA, Inc.1$12

How this compares

$2,906 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$57,535
Medicare patients
198
Services billed
1,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$92,857
MounjaroTirzepatide68$73,899
EliquisApixaban70$67,131
OzempicSemaglutide54$63,929
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$37,853
TrulicityDulaglutide17$29,716
XareltoRivaroxaban26$29,018
FarxigaDapagliflozin Propanediol17$20,711
Tresiba Flextouch U-200Insulin Degludec12$6,963
Atorvastatin Calcium512$6,293
Breo ElliptaFluticasone/Vilanterol12$6,198
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$5,047
Semglee (Yfgn) PenInsulin Glargine-Yfgn30$4,941
Levothyroxine Sodium327$4,610
Omeprazole264$4,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$108$103,61585 claims
PfizerEliquis, Abrysvo$54$71,05384 claims
Novo NordiskOzempic$161$63,92954 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Arnuity Ellipta$18$51,27081 claims
AstraZenecaFarxiga$33$20,71117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →